Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OMCL Stock Forecast 2026-2027
$37.83
Current Price
$1.72B
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to OMCL Price Targets
+85.0%
To High Target of $70.00
+58.6%
To Median Target of $60.00
+45.4%
To Low Target of $55.00
OMCL Price Momentum
-12.0%
1 Week Change
-13.6%
1 Month Change
+29.3%
1 Year Change
-16.5%
Year-to-Date Change
-31.2%
From 52W High of $55.00
+40.9%
From 52W Low of $26.85
📊 TOP ANALYST CALLS
Did OMCL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Omnicell is one of their latest high-conviction picks.
Latest OMCL Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, OMCL has a bullish consensus with a median price target of $60.00 (ranging from $55.00 to $70.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $37.83, the median forecast implies a 58.6% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Scott Schoenhaus at Keybanc, projecting a 85.0% upside. Conversely, the most conservative target is provided by Stan Berenshteyn at Wells Fargo, suggesting a 45.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OMCL Analyst Ratings
7
Buy
1
Hold
0
Sell
OMCL Price Target Range
Low
$55.00
Average
$60.00
High
$70.00
Current: $37.83
Latest OMCL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OMCL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2026 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $70.00 |
| Apr 23, 2026 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $55.00 |
| Feb 6, 2026 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Feb 2, 2026 | Benchmark | Buy | Maintains | $N/A | |
| Jan 8, 2026 | Keybanc | Overweight | Upgrade | $N/A | |
| Jan 5, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Dec 9, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| Dec 9, 2025 | Benchmark | Buy | Maintains | $N/A | |
| Oct 31, 2025 | Benchmark | Buy | Maintains | $N/A | |
| Aug 11, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jul 21, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jul 14, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| May 23, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 23, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| May 14, 2025 | Wells Fargo | Overweight | Upgrade | $N/A | |
| May 7, 2025 | Benchmark | Buy | Maintains | $N/A | |
| May 7, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 7, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| Apr 17, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Mar 20, 2025 | JP Morgan | Neutral | Maintains | $N/A |
Omnicell Inc. (OMCL) Competitors
The following stocks are similar to Omnicell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Omnicell Inc. (OMCL) Financial Data
Omnicell Inc. has a market capitalization of $1.72B with a P/E ratio of 86.0x. The company generates $1.23B in trailing twelve-month revenue with a 1.7% profit margin.
Revenue growth is +14.9% quarter-over-quarter, while maintaining an operating margin of +5.4% and return on equity of +1.6%.
Valuation Metrics
Market Cap
$1.72B
Enterprise Value
$1.70B
P/E Ratio
86.0x
PEG Ratio
-0.3x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+14.9%
Gross Margin
+45.3%
Operating Margin
+5.4%
Net Margin
+1.7%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.9%
Current Ratio
1.5x
Debt/Equity
16.1x
ROE
+1.6%
ROA
+1.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Omnicell Inc. (OMCL) Business Model
About Omnicell Inc.
What They Do
Provider of medication management solutions.
Business Model
Omnicell generates revenue by offering automated dispensing systems, pharmacy automation equipment, and software solutions to healthcare facilities. Their products enhance medication management and supply chain processes, which helps healthcare providers reduce errors and improve operational efficiency.
Additional Information
The company leverages advanced technologies like robotics, analytics, and cloud-based solutions to support the digital transformation of medication management. Omnicell's commitment to compliance and patient safety positions it as a critical player in the healthcare sector, continually adapting to meet the needs of hospitals and pharmacies.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
3,525
CEO
Mr. Randall A. Lipps
Country
United States
IPO Year
2001
Website
www.omnicell.comOmnicell Inc. (OMCL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
OMCL vs. HIMS: Which Stock Is the Better Value Option?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Jun 10, 2026
By Zacks Equity Research
Tale of the Tape
Top Robotics Stocks Worth Investing in the Second Half of 2026
Robotics stocks like ABB gain traction as 2026 marks a surge in AI-driven automation, new cobots and strategic deals shaping the sector's next growth wave.
Jun 05, 2026
By Vasundhara Sawalka
Robotics
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Jun 05, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Omnicell is rated Buy after Q1 results showed a 15% revenue increase to $310M, a 660 bps operating margin rise, and EPS of $0.55, exceeding guidance. FY 2026 EBITDA guidance raised.
Why It Matters
Omnicell's strong Q1 performance, including margin improvements and revenue growth, signals financial health and growth potential, boosting investor confidence and likely enhancing stock value.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Omnicell, Inc. (OMCL) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, sharing insights on its business and market strategies.
Why It Matters
Omnicell's presentation at a prominent conference signals its strategic direction and potential growth, influencing investor sentiment and stock performance in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a useful tool for stock selection.
Why It Matters
Zacks Style Scores provide a systematic approach to identify high-potential stocks, helping investors make informed decisions aligned with their strategies and improve portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Omnicell has appointed Dan Mandoli as the leader of its Specialty Pharmacy Services business, indicating a strategic move in their operational management.
Why It Matters
Dan Mandoli's appointment to lead Omnicell's Specialty Pharmacy Services could signal a strategic focus on expanding this segment, potentially enhancing revenue and market competitiveness.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors are comparing Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS) for value investment potential in the Medical Info Systems sector.
Why It Matters
The comparison between Omnicell and Hims & Hers indicates potential valuation opportunities, guiding investors toward more promising stock choices in the medical info sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can guide investors in selecting high-potential stocks, enhancing portfolio performance and potentially leading to better returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About OMCL Stock
What is Omnicell Inc.'s (OMCL) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Omnicell Inc. (OMCL) has a median price target of $60.00. The highest price target is $70.00 and the lowest is $55.00.
Is OMCL stock a good investment in 2026?
According to current analyst ratings, OMCL has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $37.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OMCL stock?
Wall Street analysts predict OMCL stock could reach $60.00 in the next 12 months. This represents a 58.6% increase from the current price of $37.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Omnicell Inc.'s business model?
Omnicell generates revenue by offering automated dispensing systems, pharmacy automation equipment, and software solutions to healthcare facilities. Their products enhance medication management and supply chain processes, which helps healthcare providers reduce errors and improve operational efficiency.
What is the highest forecasted price for OMCL Omnicell Inc.?
The highest price target for OMCL is $70.00 from Scott Schoenhaus at Keybanc, which represents a 85.0% increase from the current price of $37.83.
What is the lowest forecasted price for OMCL Omnicell Inc.?
The lowest price target for OMCL is $55.00 from Stan Berenshteyn at Wells Fargo, which represents a 45.4% increase from the current price of $37.83.
What is the overall OMCL consensus from analysts for Omnicell Inc.?
The overall analyst consensus for OMCL is bullish. Out of 4 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $60.00.
How accurate are OMCL stock price projections?
Stock price projections, including those for Omnicell Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 1:32 AM UTC